Razelle Kurzrock
Razelle Kurzrock, MD, is a world leader in
precision medicine and immunotherapy. As a
board-certified medical oncologist, practicing
physician, and researcher, she is recognized as
one of the 25 most important voices in
precision medicine worldwide and one of the
most highly cited scientists globally. She
recently joined the Medical College of
Wisconsin Cancer Center as Associate Director
of Clinical Research and of Precision Science,
and the Linda T and John A Mellowes Endowed
Chair of Precison Oncology, overseeing the
development of a new Precision Medicine and
Rare Cancers clinical initiative and assuming
leadership of the cancer clinical trial enterprise.
Dr. Kurzrock is best known for founding and chairing the largest Phase 1 clinical trials department in the world
while at the University of Texas MD Anderson Cancer Center. The program’s focus on the precision medicine
strategy solidified her standing as a pioneer in the development of personalized medicine.
More recently, at the University of California, San Diego Moores Cancer Center, Dr. Kurzrock established the
Rare Tumor Clinic and assumed leadership of both the Center for Personalized Cancer Therapy and Experimental
Therapeutics Program.
Dr. Kurzrock has served as principal investigator on more than 100 clinical trials and brought oversight to more
than 500 early-phase trials, with many agents yielding FDA approvals. She is the author of more than ~900 peer-
reviewed articles in a variety of elite medical journals and holds a highly exceptional Hirsch index (h-index) score
of 130, with over 75,000 citations.
Her strong record of competitive funding is comprised of approximately $125 million in lifetime funding, which
includes nearly $50 million in research support from the National Institutes of Health.
Dr. Kurzrock received her medical degree from the University of Toronto, Canada. She has four children, two
Basenjis (dogs) and is married to Philip Cohen, MD, who is a dermatologist.
Abstracts this author is presenting: